Peptide Library

In clinical trials

Digestive & weight

Glepaglutide

Evidence

Clinical trials

Class

Long-acting GLP-2 receptor agonist

/

Glepaglutide

KEY TAKEAWAY

Glepaglutide is a long-acting GLP-2 analog developed for short bowel syndrome. Glepaglutide is not FDA-approved. The FDA asked for additional trial data after an initial application.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Long-acting GLP-2 receptor agonist

Being studied for

Studied in short bowel syndrome

Key fact

Glepaglutide is not FDA-approved. The FDA asked for additional trial data after an initial application.

Route

Subcutaneous injection in trials

Evidence strength

Clinical trials

What it is

What it is

Glepaglutide is a long-acting GLP-2 analog developed for short bowel syndrome.

How it works

How it works

It activates GLP-2 receptors to support growth of the intestinal lining and improve absorption of fluid and nutrients.

Regulatory status

Regulatory status

Glepaglutide is not FDA-approved. The FDA asked for additional trial data after an initial application.

What it is used for

What it is used for

Studied in short bowel syndrome.

Side effects and risks

Side effects and risks

Reported effects included abdominal pain, injection-site reactions and swelling.

Citations

Citations

Glepaglutide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo